[company_age]5.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]AdjuTec Pharma AS is a Norwegian pharmaceutical start-up company founded in 2019 based on research in antibiotic products at the University of Oslo (UoO), Norway. The company's vision is to provide novel antibiotic resistance breakers to address the imminent threat of antimicrobial resistance (AMR) to modern medicine. AdjuTec's core technology is the synthesis of β-lactamase inhibitors (BLIs) that inactivate bacteria resistance enzymes, preserving the susceptibility of broad-spectrum antibiotics. Supported by national and EU grants, as well as private funding, AdjuTec has initiated preclinical development of its lead product, APC148. \n\nAdjuTec's unique approach to combating AMR sets it apart from its competitors. The company focuses on developing novel BLIs that target specific resistance mechanisms, offering a more targeted and potentially more effective solution than traditional broad-spectrum antibiotics. Additionally, AdjuTec's commitment to partnering with global companies for late-stage R&D and product distribution positions it for rapid growth and market penetration. \n\nAdjuTec's leadership team comprises five individuals with extensive experience in R&D, business development, and fundraising, ensuring the company's expertise in progressing its pipeline and securing funding. The company's majority owner, Professor Pål Rongved, is also the founder and CSO, demonstrating a strong commitment to AdjuTec's mission and vision. \n\nOverall, AdjuTec Pharma AS is a promising young company with a unique approach to addressing the global challenge of AMR. Its innovative technology, experienced leadership team, and strong financial backing position it for success in the rapidly growing market for antibiotic resistance breakers.[/description][ps]Novel antibiotic resistance breakers, specifically β-lactamase inhibitors (BLIs).[/ps]